Cadazolid

Cadazolid

Cadazolid

Min.Order / FOB Price:Get Latest Price

1 Gram

Negotiable

  • Min.Order :1 Gram
  • Purity: > 95%
  • Payment Terms : L/C

Keywords

1025097-10-2 cas1025097-10-2 3-?Quinolinecarboxylic acid, 1-?cyclopropyl-?6-?fluoro-?7-?[4-?[[2-?fluoro-?4-?[(5R)?-?5-?(hydroxymethyl)?-?2-?oxo-?3-?oxazolidinyl]?phenoxy]?methyl]?-?4-?hydroxy-?1-?piperidinyl]?-?1,?4-?dihydro-?4-?

Quick Details

  • Appearance:
  • Application:Cadazolid is an experimental antibiotic of the oxazolidinone class made by Actelion Pharmaceuticals Ltd. which is effective against Clostridium difficile, a major cause of drug resistant diarrhea in t
  • PackAge:inquiry
  • ProductionCapacity:10|Kilogram|Month
  • Storage:
  • Transportation:inquiry

Superiority:

BOC Sciences is committed to supplying cost-effective products and services. We provide Cadazolid. Cadazolid is an experimental antibiotic of the oxazolidinone class made by Actelion Pharmaceuticals Ltd. which is effective against Clostridium difficile, a major cause of drug resistant diarrhea in the elderly.Current drug treatments for this infection involve orally delivered antibiotics, principally fidaxomicin, metronidazole and vancomycin; the last two drugs are the principal therapeutic agents in use, but fail in approximately 20 to 45% of the cases. The drug is in Phase III trials.The drug works by inhibiting synthesis of proteins in the bacteria, thus inhibiting the production of toxins and the formation of spores. More information please visit: www.bocsci.com/cadazolid-cas-1025097-10-2-item-467964.html

Details:

BOC Sciences is committed to supplying cost-effective products and services. We provide Cadazolid. Cadazolid is an experimental antibiotic of the oxazolidinone class made by Actelion Pharmaceuticals Ltd. which is effective against Clostridium difficile, a major cause of drug resistant diarrhea in the elderly.Current drug treatments for this infection involve orally delivered antibiotics, principally fidaxomicin, metronidazole and vancomycin; the last two drugs are the principal therapeutic agents in use, but fail in approximately 20 to 45% of the cases. The drug is in Phase III trials.The drug works by inhibiting synthesis of proteins in the bacteria, thus inhibiting the production of toxins and the formation of spores. More information please visit: www.bocsci.com/cadazolid-cas-1025097-10-2-item-467964.html

 

 

Related Searches

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View